These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. An evaluation of ibrexafungerp for the treatment of invasive candidiasis: the evidence to date. Colombo RE; Vazquez JA Expert Opin Pharmacother; 2021 May; 22(7):797-807. PubMed ID: 33599551 [TBL] [Abstract][Full Text] [Related]
6. Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Gamal A; Chu S; McCormick TS; Borroto-Esoda K; Angulo D; Ghannoum MA Front Cell Infect Microbiol; 2021; 11():642358. PubMed ID: 33791244 [TBL] [Abstract][Full Text] [Related]
7. Ibrexafungerp: A new triterpenoid antifungal. Sucher AJ; Thai A; Tran C; Mantena N; Noronha A; Chahine EB Am J Health Syst Pharm; 2022 Dec; 79(24):2208-2221. PubMed ID: 36083109 [TBL] [Abstract][Full Text] [Related]
8. In vitro activity of ibrexafungerp against Candida species isolated from blood cultures. Determination of wild-type populations using the EUCAST method. Mesquida A; Díaz-García J; Sánchez-Carrillo C; Muñoz P; Escribano P; Guinea J Clin Microbiol Infect; 2022 Jan; 28(1):140.e1-140.e4. PubMed ID: 34619396 [TBL] [Abstract][Full Text] [Related]
13. Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis. Azie N; Angulo D; Dehn B; Sobel JD Expert Opin Investig Drugs; 2020 Sep; 29(9):893-900. PubMed ID: 32746636 [TBL] [Abstract][Full Text] [Related]
14. Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris. Kordalewska M; Lee A; Park S; Berrio I; Chowdhary A; Zhao Y; Perlin DS Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632013 [No Abstract] [Full Text] [Related]
15. Rezafungin Helleberg M; Jørgensen KM; Hare RK; Datcu R; Chowdhary A; Arendrup MC Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015032 [TBL] [Abstract][Full Text] [Related]
16. Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections. Angulo DA; Alexander B; Rautemaa-Richardson R; Alastruey-Izquierdo A; Hoenigl M; Ibrahim AS; Ghannoum MA; King TR; Azie NE; Walsh TJ J Fungi (Basel); 2022 Oct; 8(11):. PubMed ID: 36354888 [TBL] [Abstract][Full Text] [Related]
17. In Vitro activity of ravuconazole against Candida auris and vaginal candida isolates. Dong J; Liang G; Zheng H; Kan S; Song N; Zhang M; Liu W Mycoses; 2021 Jun; 64(6):651-655. PubMed ID: 33609301 [TBL] [Abstract][Full Text] [Related]